Chemocentryx, Inc.

Lianfa Li

Penglie Zhang

Andrew M K Pennell

Wei Yu Chen

Yibin Zeng

Jay Patrick Powers

Pingchen Fan

Jeffrey P McMahon

Xi Chen

Kevin Lloyd Greenman

John J Kim Wright

Manmohan Reddy Leleti

Yandong Li

Junfa Fan

Yuan Xu

Edward J Sullivan

Mark M Gleason

Rebecca M Lui

Antoni Krasinski

Juan Carlos Jaen

Dean R Dragoli

Valeri Martichonok

Jeffrey P McMAHON

Andrew Mk Pennell

Wei Chen

Jeffrey P Mcmahon

Andrew M Pennell

John J Wright

John Kim J Wright

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Azaindazole compounds and methods of use

Aza-aryl 1H-pyrazol-1-YL benzene sulfonamides

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

Modulators of CXCR7

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are 3-imidazoyl-pyrazolo[3,4-b]pyridine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

3-(imidazolyl)-pyrazolo[3,4-b] pyridines

Provided are methods for the treatment of rheumatoid arthritis using compounds of formula Ia and Ib: or a pharmaceutically acceptable salt, hydrate or N-oxide thereof.

3-(imidazolyl)-pyrazolo[3,4-b]pyridines

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally monocyclic and bicyclic compounds and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

Monocyclic and bicyclic compounds and methods of use

The present invention provides compounds having formula (I): 

OXO-imidazolidines as modulators of chemokine receptors

Methods are provided for the synthesis of 1-[4-(substituted phenyl)-piperazin-1-yl ] -2- [3-(1H-imidazol-2-yl)-pyrazolo [3,4-b]pyridin-1-yl]-ethanone compounds via construction of the imidazole portion onto the corresponding aldehyde or nitrile compounds.

4-phenylpiperdine-pyrazole CCR1 antagonists

Piperidine derivatives and methods of use

Growing community of inventors

Palo Alto, CA, United States of America

Lianfa Li